Thc Therapeutics Stock Fundamentals
| THCT Stock | USD 0.0002 0.0001 33.33% |
THC Therapeutics fundamentals help investors to digest information that contributes to THC Therapeutics' financial success or failures. It also enables traders to predict the movement of THC Pink Sheet. The fundamental analysis module provides a way to measure THC Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to THC Therapeutics pink sheet.
THC |
THC Therapeutics Company Return On Asset Analysis
THC Therapeutics' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current THC Therapeutics Return On Asset | -5.57 |
Most of THC Therapeutics' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, THC Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, THC Therapeutics has a Return On Asset of -5.5725. This is 36.31% lower than that of the Health Care Equipment & Supplies sector and significantly lower than that of the Health Care industry. The return on asset for all United States stocks is notably higher than that of the company.
THC Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining THC Therapeutics's current stock value. Our valuation model uses many indicators to compare THC Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across THC Therapeutics competition to find correlations between indicators driving THC Therapeutics's intrinsic value. More Info.THC Therapeutics is rated fourth in return on asset category among its peers. It is rated third in current valuation category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the THC Therapeutics' earnings, one of the primary drivers of an investment's value.THC Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses THC Therapeutics' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of THC Therapeutics could also be used in its relative valuation, which is a method of valuing THC Therapeutics by comparing valuation metrics of similar companies.THC Therapeutics is currently under evaluation in return on asset category among its peers.
THC Fundamentals
| Return On Asset | -5.57 | |||
| Current Valuation | 1.57 M | |||
| Shares Outstanding | 34.15 M | |||
| Shares Owned By Insiders | 30.84 % | |||
| Price To Earning | 1.25 X | |||
| Price To Book | 46.07 X | |||
| EBITDA | (1.06 M) | |||
| Net Income | (1.89 M) | |||
| Cash And Equivalents | 3.82 K | |||
| Total Debt | 925.89 K | |||
| Debt To Equity | 18.70 % | |||
| Current Ratio | 0.01 X | |||
| Book Value Per Share | (0.15) X | |||
| Cash Flow From Operations | (388.48 K) | |||
| Earnings Per Share | (0.09) X | |||
| Beta | 1.71 | |||
| Market Capitalization | 1.09 M | |||
| Total Asset | 480.07 K | |||
| Z Score | -6.0 | |||
| Net Asset | 480.07 K |
About THC Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze THC Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of THC Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of THC Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.It is involved in the development of dHydronator, a sanitizing herb dryer for drying and sanitizing of freshly harvested cannabis, other herbs, flowers, and tea leaves. THC Therapeutics, Inc. was incorporated in 2007 and is based in Las Vegas, Nevada. Thc Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 1 people.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for THC Pink Sheet Analysis
When running THC Therapeutics' price analysis, check to measure THC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy THC Therapeutics is operating at the current time. Most of THC Therapeutics' value examination focuses on studying past and present price action to predict the probability of THC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move THC Therapeutics' price. Additionally, you may evaluate how the addition of THC Therapeutics to your portfolios can decrease your overall portfolio volatility.